$CORT News
Last published 1w ago
- 1w agoCORTCORCEPT THERAPEUTICS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoCORTCorcept Therapeutics Q3 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to the CoreSep Therapeutics Q3 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To a
- 1w agoCORTCorcept Therapeutics Q3 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to the CoreSep Therapeutics Q3 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To a
- 2w agoCORTCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day
- 2w agoCORTCorcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerBusiness WireLifyorli (relacorilant) in combination with nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the more
- 3w agoCORT2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesBusiness WireJoint recommendation cites Corcept’s CATALYST study on the prevalence and treatment of hypercortisolism in patients whose blood sugar remains high despite use of multiple glucose-lowering medications Corcept
- 1mo agoCORTCorcept Announces Planned Leadership TransitionBusiness WireSean Maduck to Retire; Justin Gunn Appointed President, Endocrinology Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat
- 1mo agoCORTCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)Business WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 3mo agoCORTCorcept Therapeutics Q2 2026 Earnings Conference Call - CORCEPT THERAPEUTICS INCEarnings Call TranscriptsThank you for standing by and welcome to the Corset Therapeutics Second Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a que
- 3mo agoCORTCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate UpdateBusiness WireRevenue of $256.1 million, a 32 percent increase over the same period in 2025 Korlym® and authorized generic product revenue of $208.6 million Lifyorli™ product revenue of $47.6 million Increase in 2026
- 3mo agoCORTCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at
- 4mo agoCORTKuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated...
- 4mo agoCORTKuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law FirmGlobeNewswireNEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ:CORT) breached their
- 4mo agoCORTCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's SyndromeBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 5mo agoCORTCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®Business WireNew data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically
- 5mo agoCORTCorcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane ExposureBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 5mo agoCORTCorcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's SyndromeBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 6mo agoCORTCorcept Therapeutics Q1 2026 Earnings Conference Call - Corcept TherapeuticsEarnings Call TranscriptsThank you for standing by and welcome to Course Up Therapeutics first quarter 2026 earnings conference call. Currently all participants are in a listen-only mode. After the speaker's presentation, there will be a questio
- 6mo agoCORTCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateBusiness WireRevenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million Net loss of $31.8 million, compared to net income of $20.5 million in first
- 6mo agoCORTCorcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral SclerosisBusiness Wire87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001) Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the
- 6mo agoCORTCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at
- 6mo agoCORTCorcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026Business WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 7mo agoCORTCorcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian CancerBusiness WireData demonstrate a 35 percent reduction in risk of death Lifyorli, in combination with nab-paclitaxel, added to NCCN Guidelines® as a preferred regimen Lifyorli approved by the FDA in March 2026 Corcept
- 7mo agoCORTCorcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific SessionBusiness WireHypercortisolism identified in 27.3 percent of patients with resistant hypertension Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications
- 7mo agoCORTFDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian CancerBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 7mo agoCORTApproval of Lifyorlitm, Nda #220641 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 03/25/2026; Drug Name: Lifyorlitm, Nda #220641; Active Ingredients: RELACORILANT; Company: Corcept Therap; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220641
- 8mo agoCORTREMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026Business WireKirby McInerney LLP reminds Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class
- 8mo agoBSXCORTNKTRUNCYImportant Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 10, 2026 (GLOBE NEWSWIRE) -- Boston Scientific Corporation (NYSE:BSX): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Boston Scientific Corporation
- 8mo agoCORTThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares ...
- 8mo agoCORTKDMOHUNCYImportant Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Corcept Therapeutics, Inc. (NASDAQ:CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc.
- 8mo agoCORTITGRKDMOHImportant Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Corcept Therapeutics, Inc. (NASDAQ:CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc.
- 8mo agoCORTThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORTPR NewswireThe Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares ...
- 8mo agoCORTFIVNITGRKDImportant Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, Inc. (NASDAQ: FIVN); Integer Holdings Corp. (NYSE: ITGR); and Kyndryl Holdings (NYSE: KD): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswirePHILADELPHIA, March 02, 2026 (GLOBE NEWSWIRE) -- Corcept Therapeutics, Inc. (NASDAQ:CORT): WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Corcept Therapeutics, Inc.
- 8mo agoCORTCORCEPT THERAPEUTICS Q4 2025 EARNINGS CONFERENCE CALL - Corcept TherapeuticsEarnings Call TranscriptsThank you for standing by, and welcome to CourseUp Therapeutics' fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a que
- 8mo agoCORTCorcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate UpdateBusiness Wire2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics
- 8mo agoCORTCorcept Provides Update on Patent Dispute with Teva PharmaceuticalsBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 8mo agoCORTCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a
- 9mo agoCORTBerman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug ApplicationGlobeNewswireBOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated
- 9mo agoCORTCorcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover LossesGlobeNewswireBOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (NASDAQ:CORT) for potential securities law violations. Investors who have lost money in their Corcept
- 10mo agoCORTCorcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with HypercortisolismBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 1y agoCORTCorcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate UpdateBusiness WireRevenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash
- 1y agoCORTCorcept Therapeutics Q3 2025 Earnings Conference Call - Corcept TherapeuticsEarnings Call TranscriptsThank you for standing by, and welcome to Corset Therapeutics' third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a questi
- 1y agoCORTCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at
- 1y agoCORTCorcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor TreatmentBusiness WireNew data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker
- 1y agoCORTCorcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 1y agoCORTCorcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025Business WireCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
- 1y agoCORTFDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerBusiness WireFDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat
- 1y agoCORTCorcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCORTCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate UpdateBusiness WireRevenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter
- 1y agoCORTCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness WireCorcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025. The company will also host a conference call that day at